Kaplan–Meier analysis of PFS and OS with durvalumab–ceralasertib in subgroups defined by the presence or absence of the adverse prognostic factors described above (Extended Data Fig. 4) indicated that outcomes were similar in patients with primary or acquired resistance, PD-L1-negative or PD-L1-positive tumors, squamous or nonsquamous tumor histology, high or low TMB, and STK11 or KRAS mutant or wild-type tumors. Here, KRAS is linked to neoplasm.